IONS Stock Chart & Stats
$1010.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1010.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$960.00 - $1,310.00
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
$154.43B
Enterprise Value$13.25K
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$2.42B
Price to Earnings (P/E)―
Beta0.01
Next Earnings
Nov 04, 2026EPS Estimate
-20.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.46
Shares Outstanding166,184,330
10 Day Avg. Volume5
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)25.88
Price to Sales (P/S)13.41
P/FCF Ratio-39.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,444.65Price Target Upside43.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)-62.55
Revenue Forecast (FY)$15.67B
Bulls Say, Bears Say
Bulls Say
Independent Rare-neurology CommercializationZANVASTRO approval expands Ionis’s role from drug discovery and partnering into independent commercialization in rare neurology. The launch, patient-support infrastructure, and planned international regulatory activity can build durable capabilities and future product economics.
Growing Commercial Product BaseDAWNZERA’s rapid sequential sales growth and meaningful U.S. market share demonstrate early adoption of a commercial medicine. Combined with TRYNGOLZA’s launch, this broadens recurring product-related revenue and reduces reliance solely on licensing milestones.
Strong Liquidity RunwayA substantial cash and investment balance gives Ionis capacity to fund late-stage development, launches, and pipeline advancement while operating losses continue. The projected runway supports execution through 2028 and reduces near-term dependence on external financing.
Bears Say
Persistent Cash Burn And Operating LossesPersistent negative operating and free cash flow means Ionis is not yet funding its activities internally, despite high gross margins. Continued losses can consume liquidity, constrain investment choices, and make the path to sustainable cash generation dependent on successful launches and milestones.
Elevated Leverage And Thin EquityHigh leverage combined with a relatively thin equity base reduces financial flexibility while the company remains unprofitable. Debt obligations can increase pressure on future cash allocation and leave less resilience if development programs or commercial launches underperform.
Late-stage Partnered Pipeline SetbacksThe pelacarsen failure weakens a significant partnered cardiovascular opportunity and illustrates the binary risk in Ionis’s late-stage pipeline. Although biomarker reductions remained substantial, the clinical endpoint miss may reduce future milestones, royalties, and progress toward breakeven.
Ionis Pharmaceuticals News
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $960.00 and its highest was $1310.00 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $154.43B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Nov 04, 2026 which is in 50 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Jul 29, 2026. The company reported -$11.713 earnings per share for the quarter, beating the consensus estimate of -$18.487 by $6.773.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -20.57.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 166,184,330 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$11.713 in its last earnings report, beating expectations of -$18.487. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in MX:IONS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ionis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,444.65 (43.03% Upside)
$1,444.65 (43.03% Upside)
Blogger Sentiment
Bullish
MX:IONS Sentiment 86%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth $18.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ionis Pharmaceuticals
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
IONS Company Deck
IONS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong execution across approvals, launches and financials: a landmark approval and early commercial uptake for TRYNGOLZA, accelerating DAWNZERA adoption, solid revenue growth (Q2 revenue $268M, H1 $514M; Q2 commercial revenue $119M up 15% YoY) and a healthy cash position ($2.1B). The company reiterated 2026 guidance and a path to cash-flow breakeven in 2028 while advancing a robust pipeline with multiple near-term catalysts (Zilganersen PDUFA Sept 22, Bepirovirsen PDUFA Oct 26, Pelacarsen readout). Key challenges include the negative CARDIO-TTRansform outcome for Eplontersen, short-term reimbursement frictions (medical exceptions, ICD-10 coding), the Q2 impact from an intentional TRYNGOLZA price reduction, and dependence on partner trial readouts that could affect medium-term profitability. Overall, positives — approvals, launch momentum, strong revenue growth and cash runway — meaningfully outweigh the headwinds described.View all MX:IONS earnings summariesIONS Revenue Breakdown
60.82% R&D
39.18% Commercial
IONS Stock 12 Month Forecast
Average Price Target
$1,444.65
▲(43.03% Upside)